Cover Image
市場調查報告書

孤兒藥的全球市場分析

Global Orphan Drugs Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 351312
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
孤兒藥的全球市場分析 Global Orphan Drugs Market Report: 2016 Edition
出版日期: 2016年02月01日 內容資訊: 英文 56 Pages
簡介

本報告提供全球孤兒藥 (罕見疾病治療藥) 的市場最新趨勢與未來展望相關分析,孤兒藥的整體市場結構和趨勢預測,各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業簡介、業績、策略等相關調查與考察。

第1章 罕見疾病:簡介

  • 原因
  • 預防法
  • 診斷方法
  • 治療選擇
  • 孤兒藥 (罕見疾病治療藥)

第2章 市場分析

  • 全球孤兒藥市場
    • 市場規模
    • 市場成長率
    • 市場區隔

第3章 各地區的分析

  • 美國的孤兒藥市場
    • 超孤兒藥市場
  • 加拿大
  • 歐洲
  • 日本

第4章 市場動態

  • 主要趨勢與趨勢
  • 市場成長的推動要素
  • 課題

第5章 競爭環境

  • 全球市場
    • 市場佔有率
    • 產品比較
  • 美國市場

第6章 企業簡介

  • Roche Holdings
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • Novartis
  • Celgene Corporation
  • Novo Nordisk
  • Eli Lilly and Company

圖表一覽

目錄

A rare disease is the one that occurs uncommonly or rarely in the general population. However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare diseases. These drugs are referred to be “orphan” as under normal conditions because these drugs are not cost effective to be developed by the pharmaceuticals industry, intended for a small number of patients suffering from rare conditions.

Increasing sales of prescription drugs, substantial benefits for new entrants in rare disease drug market, increased spending on medicines, rising healthcare expenditure and improving economic conditions of nations are some of the significant factors driving growth of the Orphan drugs market. However, the growth of the market is hindered by certain challenges including tougher regulatory approvals, limitation on charging higher prices and no approved drugs for several rare diseases including Polychethemia Vera (PV).

The global orphan drugs market is expected to see numerous developments including approval of several Ultra-Rare drugs, increasing scope of Gene therapy, development of drugs for rare blood disease, higher success prospects for Hematology compared to Solid Tumors, attractive pricing option for orphan drug competitors and striking opportunities in developing orphan drugs.

The report, “Global Orphan Drugs Market” analyzes the current prevailing condition of the market along with its future scope of development. The global market along with specific market of the U.S., Canada, Europe and Japan, is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Contents

1. Orphan Diseases: Introduction

  • 1.1. Causes
  • 1.2. Prevention
  • 1.3. Diagnosis
  • 1.4. Treatment Options
  • 1.5. Orphan Drugs

2. Market Analysis

  • 2.1. Global Orphan Drugs Market
    • Market Value
    • Growth Rate
    • Market Segmentation
      • 2.1.1. Non-Hodgkin's Lymphoma (NHL) Market

3. Regional Analysis

  • 3.1. The U.S. Orphan Drugs Market
    • Applications & Designations
    • Spending Growth Forecast
  • 3.1.1. The Ultra-Rare Drugs Market
  • 3.2. Canada
  • 3.3. Europe
  • 3.4. Japan

4. Market Dynamics

  • 4.1. Key Trends and Developments
    • 4.1.1. Striking Opportunities in Developing Orphan Drugs
    • 4.1.2. Attractive Pricing Option for Orphan Drug Companies
    • 4.1.3. Higher Success Prospect for Hematology vs. Solid Tumors
    • 4.1.4. Development of Drugs for Rare Blood Diseases
    • 4.1.5. Increasing Scope of Gene Therapy
    • 4.1.6. Approval of Ultra-Orphan Drugs
  • 4.2. Growth Drivers
    • 4.2.1. Increasing Sales of Prescription Drugs
    • 4.2.2. Substantial Benefits for New Entrants in Rare Diseases Market
    • 4.2.3. Increased Spending on Medicines
    • 4.2.4. Rising Healthcare Expenditure
    • 4.2.5. Rising Global GDP
  • 4.3. Challenges
    • 4.3.1. Limitation on Charging High Price for Orphan Drugs
    • 4.3.2. No Approved Drug for Polycythemia Vera First-line Treatment
    • 4.3.3. Tough Regulatory Approval for Orphan Drugs

5. Competitive Landscape

  • 5.1. Global Market
    • Market Share
    • Product Comparison
  • 5.2. The U.S. Market
    • Market Share
    • Product Comparison

6. Company Profiles

  • 6.1. Roche Holdings
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Novartis
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Celgene Corporation
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Novo Nordisk
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies
  • 6.5. Eli Lilly and Company
    • 6.5.1. Business Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Business Strategies

List of Charts

  • Global Orphan Drugs Market (2010-2015E)
  • Orphan Drugs as Percent of Prescription Drugs (2010-2015E)
  • Global Orphan Drugs Market by Type (2014)
  • Average Cost per Patient for Orphan & Non-orphan Drugs (2010-2014)
  • Median Cost per Patient for Orphan & Non-orphan Drugs (2010-2014)
  • Non-Hodgkin's Lymphoma Stage at Diagnosis (2014)
  • Non-Hodgkin's Lymphoma (NHL) by Sub-Types (2014)
  • Incidence of Non-Hodgkin's Lymphoma in Major Countries (2010-2014)
  • Orphan Drug (OD) Applications & Designations per Year (2009-2014)
  • The U.S. Orphan Drugs Spending (2009-2014E)
  • The U.S. Orphan Drugs Spending Forecast (2015-2018)
  • Prevalence of LEMS in the U.S. (2015-2020E)
  • Firdapse Drug's Sales and Penetration Rate (2015-2020E)
  • The U.S. Epilepsy, Tourette and West Syndrome Prevalence (2015-2020E)
  • The U.S. CPP-115 Revenue (2018-2022)
  • Orphan Drugs Spending in Canada (2009-2014E)
  • Canada's Orphan Drugs Spending Forecast (2015-2018)
  • Orphan Drug Designations per Year in EU (2009-2014)
  • Orphan Designations in EU by Indication (2014)
  • Orphan Disease Prevalence in EU by Indication (2014)
  • Orphan Designations per Year in Japan (2009-2014)
  • Median Patient Volume in Phase 3 Trial
  • Median Phase 3 Trial Costs
  • Success Probability for Hematology vs. Solid Tumors
  • Global Sales of Prescription Drugs (2010-2015E)
  • Annual Prices of Key Orphan Drugs in the U.S
  • Global Spending on Medicines (2010-2020E)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Gross Domestic Product Growth (2009-2014)
  • Ranking of Factors for Inclusion/Restriction in Plans by the U.S. Payers
  • Global Orphan Drugs Market by Company (2014)
  • Global Orphan Drugs Market by Company (2020E)
  • The U.S. Orphan Drugs Market by Company (2014)
  • Roche's Revenue by Business Segments (2014)
  • Roche's Revenue and Net Income (2010-2014)
  • Novartis Revenue by Business Segments (2014)
  • Novartis Revenues (2010-2014)
  • Celgene Corporation Revenue by Segments (2013/2014)
  • Celgene Corporation Revenue and Net Income (2010-2014)
  • Research and Development Expense by Category (2012-2014)
  • Novo Nordisk Revenue Share by Business Segments (2014)
  • Novo Nordisk's Sales and Net Income (2010-2014)
  • Eli Lilly's Revenue by Segments (2014)
  • Eli Lilly's Sales and Net Income (2010-2014)

List of Tables

  • Orphan Drugs as Proportion of New Molecular Entities Approved in the U.S. (2010-2014)
  • Orphan Drugs Approved in Japan (2014)
  • Prices and Prevalence of Orphan Drugs in the U.S
  • Current Ongoing Trials for Rare Blood Diseases
  • Recently Approved Ultra-Orphan Drugs
  • Globally Operating Top Orphan Drugs Competitor's Overview
  • The U.S. Orphan Drugs Competitor's Overview (2014)
Back to Top